KeyBanc raised the firm’s price target on Conmed to $141 from $131 and keeps an Overweight rating on the shares, citing higher estimates and shift to 2025 valuation. Results and upwardly revised guidance reflected macro strength, as well as core growth drivers, and the firm was encouraged it proactively addressed potential competition for AirSeal.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNMD:
- Conmed raises FY23 EPS view $3.40-$3.55 from $3.30-$3.50, consensus $3.42
- Conmed reports Q2 adjusted EPS 83c, consensus 79c
- CNMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue